PROTOCOL SPECIFIC RESEARCH SUPPORT

特定于协议的研究支持

• 批准号: 8436455
• 负责人: William L. Carroll
• 金额: $ 1.62万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-03-01 至 2018-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8436455
• 关键词: Accounting; Area; Breast; Cancer Center; Cancer Center Support Grant; Cancer Control; Categories; Clinical Trials; Collaborations; Development; Developmental Therapeutics Program; Disease Management; Faculty; Fostering; Funding; Future; Goals; Grant; Gynecologic Oncology; Institutes; Instruction; Laboratories; Leadership; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Mentorship; Monitor; Patients; Pediatric Oncology; Phase; Population Sciences; Protocols documentation; Radiation Oncology; Recommendation; Recruitment Activity; Research; Research Personnel; Research Support; Resources; Scientific Advances and Accomplishments; Surgical Oncology; Therapeutic; Therapy Clinical Trials; Thoracic Oncology; design; interdisciplinary collaboration; meetings; neuro-oncology; novel; pilot trial; prevent; programs

PROJECT SUMMARY (See instructions): CCSG funds for Protocol Specific Research Support (PSRS) are used for development of NYUCI investigator initiated early phase protocols. The NYUCI places a high priority on such studies since they represent one of the most promising benefits of the NCI Cancer Centers Program. Approximately 23% of NYUCI therapeutic trials are Investigator-Initiated Trials. Accrual to investigator-initiated studies at NYUCI has increased by almost 10% over the last funding period and this category now accounts for 68.6% of all therapeutic accruals. Protocols considered for PSRS funds have to meet the following requirements: 1) Designation of high priority by a NYUCI Disease Management Group and/or CCSG Scientific Research Program; 2) Approval and high merit score by the Protocol Review & Monitoring Committee (PRMC); 3) Clearance provided by the Clinical Trials Office that all other institutional requirements and investigator's conduct of research are met; and 4) Recommendation by the PRMC, Cancer Institute Director and CCIC for funding. The CCIC, in conjunction with the PSRS Chair, review all relevant approvals, scores, and the financial assessment of the trial to make the determination about PSRS funding.

项目总结（见说明）： CCSG为方案特定研究支持（PSRS）提供的资金用于制定NYUCI研究者发起的早期方案。NYUCI高度重视这些研究，因为它们代表了NCI癌症中心计划最有希望的好处之一。大约23%的NYUCI治疗试验是研究者发起的试验。在上一个资助期内，NYUCI的药物启动研究的应计费用增加了近10%，这一类别现在占所有治疗应计费用的68.6%。 为PSRS基金考虑的协议必须满足以下要求： 1)NYUCI疾病管理小组和/或CCSG科学研究计划指定的高优先级; 2)方案审查和监测委员会的批准和高分; 3)临床试验办公室提供的所有其他机构要求和 符合研究者的研究要求;以及 4)由PRMC、癌症研究所所长和CCIC推荐资助。 CCIC与PSRS主席一起审查试验的所有相关批准、评分和财务评估，以确定PSRS资金。